counterion raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-28 and is reviewed periodically as new material appears.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
==== Use in combination ==== The first-line treatment for brucellosis is a combination of doxycycline and streptomycin. The second-line treatment is a combination of doxycycline and rifampicin (rifampin).
=== Physical pressures === Elite athletes have financial competitive motivations that cause them to dope and these motivations differ from that of recreational athletes. The common theme among these motivations is the pressure to physically perform. In a study of 101 individuals, 86% responded that their use of performance enhancement drugs were influenced by the potential athletic success, 74% by the economic aspect, and 30% by self-confidence and social recognition related reasons. In another study of 40 people, it was concluded that athletes used performance enhancement drugs for healing purposes so that they were an able competitor for the economic rewards involved with elite sports. Physical pressures often overlap with social pressures to have a certain body build. This is the case with muscle dysmorphia, where an athlete wants a more muscular physique for functionality and self- image purposes. The most popular motive for athletes to take supplements is to prevent any nutrient deficiencies and to strengthen the immune system. These factors all focus on improving the body for performance.
== Further reading == Blanco, Carlos; Alegría, Analucía A.; Liu, Shang-Min; Secades-Villa, Roberto; Sugaya, Luisa; Davies, Carrie; Nunes, Edward V. (2012). "Differences Among Major Depressive Disorder with and Without Co-occurring Substance Use Disorders and Substance-Induced Depressive Disorder". The Journal of Clinical Psychiatry. 73 (6): 865–873. doi:10.4088/JCP.10m06673. PMID 22480900. Sciacca, Kathleen_2009. "Best Practices for Dual Diagnosis Treatment and Program Development: Co-occurring Mental Illness and Substance Disorders in Various Combinations". In Angela Brown-Miller (ed.). The Praeger International Collection on Addictions. Vol. 3. Praeger. pp. 161–188.{{cite book}}: CS1 maint: numeric names: authors list (link) Sciacca, K. (2011). "Integrated Group Treatment for People Experiencing Mental Health - Substance Use Problems". In David B. Cooper (ed.). Intervention in Mental Health - Substance Use. Radcliffe Pub. pp. 114–127. Sciacca, K.; Hatfield, A. B. (1995). "The Family and the Dually Diagnosed Patient". In Lehman, A. F.; Dixon, L. B. (eds.). Double Jeopardy. Harwood Academic Publishers. pp. 193–209. Giglioti, M. A. (October 1986). "Program Initiatives for Dually-Diagnosed at Harlem Valley Psychiatric Center. Dual Diagnosis -Co-occurring Disorders". New York State Commission on Quality of Care Publication (28). Samet S, Nunes E, Hassin D, et al. (2006). "Diagnosis of comorbid psychiatric disorders in substance users assesses with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV". American Journal of Psychiatry.
=== Pressure reduction === Pressure must be removed from high risk body areas by frequent changes in position in bed or chair, including turning side to side. Chair cushions and air mattresses should be used for immobile patients. Heels should be off of the bed.
Nitro cold brew is a variation of cold brew coffee that adds nitrogen gas to create a smooth texture, delivering the nitrogenated coffee from a nitrogen beer tap system. It was introduced in the early 2010s.
Sources: en.wikipedia.org
Glutathione (GSH, ) is a tripeptide made of the amino acids glutamate, cysteine, and glycine. It is an antioxidant in plants, animals, fungi, and some bacteria and archaea. Glutathione is capable of preventing damage to important cellular components caused by sources such as reactive oxygen species, free radicals, peroxides, lipid peroxides, and heavy metals. It is the most abundant and important low-molecular-mass thiol within most cell types. It is synthesized by attaching cysteine to the carboxyl group of the glutamate side chain with a gamma peptide linkage, and to glycine with a normal peptide bond.
== History == In 1799, British chemist Charles Hatchett experimented with decalcifying the shells of various crustaceans, finding that a soft, yellow and cartilage-like substance was left behind that is now known to be chitin. In 1859, French physiologist Charles Marie Benjamin Rouget found that boiling chitin in potassium hydroxide solution could deacetylate it to produce a substance that was soluble in dilute organic acids, that he called chitine modifiée. In 1894, German chemist Felix Hoppe-Seyler named the substance chitosan. From 1894 to 1930 there was a period of debate and confusion over the exact composition of chitin and particularly whether animal and fungal forms were the same chemicals. In 1930 the first chitosan films and fibres were patented but competition from petroleum-derived polymers limited their uptake. It was not until the 1970s that there was renewed interest in the compound, spurred partly by laws that prevented the dumping of untreated shellfish waste.
== Medical uses == d-ribose has been suggested for use in management of congestive heart failure (as well as other forms of heart disease) and for chronic fatigue syndrome (CFS), also called myalgic encephalomyelitis (ME) in an open-label non-blinded, non-randomized, and non-crossover subjective study. Supplemental d-ribose can bypass part of the pentose phosphate pathway, an energy-producing pathway, to produce d-ribose-5-phosphate. The enzyme glucose-6-phosphate-dehydrogenase (G-6-PDH) is often in short supply in cells, but more so in diseased tissue, such as in myocardial cells in patients with cardiac disease. The supply of d-ribose in the mitochondria is directly correlated with ATP production; decreased d-ribose supply reduces the amount of ATP being produced. Studies suggest that supplementing d-ribose following tissue ischemia (e.g. myocardial ischemia) increases myocardial ATP production, and therefore mitochondrial function. Essentially, administering supplemental d-ribose bypasses an enzymatic step in the pentose phosphate pathway by providing an alternate source of 5-phospho-d-ribose 1-pyrophosphate for ATP production. Supplemental d-ribose enhances recovery of ATP levels while also reducing cellular injury in humans and other animals. One study suggested that the use of supplemental d-ribose reduces the instance of angina in men with diagnosed coronary artery disease. d-Ribose has been used to treat many pathological conditions, such as chronic fatigue syndrome, fibromyalgia, and myocardial dysfunction.
After a twenty-year hiatus, the station was officially relaunched on 4 April 2011. Its radio counterpart Radio Mogadishu also broadcasts from the capital. Somaliland National TV and Puntland TV and Radio air from the northern regions. Additionally, Somalia has several private television and radio networks. Among these are Horn Cable Television and Universal TV. The political Xog Doon and Xog Ogaal and Horyaal Sports broadsheets publish out of the capital. There are also a number of online media outlets covering local news, including Garowe Online, Wardheernews, and Puntland Post. The internet country code top-level domain (ccTLD) for Somalia is .so. It was officially relaunched on 1 November 2010 by.SO Registry, which is regulated by the nation's Ministry of Posts and Telecommunications. In November 2013, following a Memorandum of Understanding signed with Emirates Post in April of the year, the federal Ministry of Posts and Telecommunications officially reconstituted the Somali Postal Service (Somali Post). In October 2014, the ministry also relaunched postal delivery from abroad.
[N]o peer competitor has yet emerged more than a decade after the end of US-Soviet bipolarity to balance against the United States. Contrary to realist predictions, unipolarity has not provided the global alarm to restore a balance of power.
Sources: en.wikipedia.org
Myrophine (Myristylbenzylmorphine) is an opiate analogue that was developed in 1952. It is a derivative of morphine. Myrophine is substituted with a 3-benzyl group and a 6-myristyl chain. It is metabolised to form benzylmorphine and then further to morphine, and so is a long-acting prodrug for morphine, but with a slow onset of effects. It is weaker than morphine as an analgesic but longer-lasting in effects, and was thought to have more local anesthetic effect than morphine, though with a somewhat greater tendency to cause reactions like itching and rash. In addiction studies conducted in human subjects in the 1950s, myrophine did not substitute for morphine in withdrawal, did not produce notable morphine-like effects, and did not produce addiction or dependence regardless of dose or how it was administered. Consequently, it was thought to be useful in treating pain in addicts who were being detoxified from other opioid drugs. It is a Schedule I drug in the US, considered to have high potential for abuse and no medical applications, and is controlled under international drug conventions. Myrophine is almost invariably used as the hydrochloride (free base conversion ratio 0.94) and has a DEA Administrative Controlled Substance Control Number of 9308. Myrophine is a Class A controlled substance in the UK, and is on the UN's Yellow list.
== Hazards == Radium is highly radioactive, as is its immediate decay product, radon gas. When ingested, 80% of the ingested radium leaves the body through the feces, while the other 20% goes into the bloodstream, mostly accumulating in the bones. This is because the body treats radium as calcium and deposits it in the bones, where radioactivity degrades marrow and can mutate bone cells. Exposure to radium, internal or external, can cause cancer and other disorders, because radium and radon emit alpha and gamma rays upon their decay, which kill and mutate cells. Radium is generally considered the most toxic of the radioactive elements. Some of the biological effects of radium include the first case of "radium-dermatitis", reported in 1900, two years after the element's discovery. The French physicist Antoine Becquerel carried a small ampoule of radium in his waistcoat pocket for six hours and reported that his skin became ulcerated. Pierre Curie attached a tube filled with radium to his arm for ten hours, which resulted in the appearance of a skin lesion, suggesting the use of radium to attack cancerous tissue as it had attacked healthy tissue. Handling of radium has been blamed for Marie Curie's death, due to aplastic anemia, though analysis of her levels of radium exposure done after her death find them within accepted safe levels and attribute her illness and death to her use of radiography. A significant amount of radium's danger comes from its daughter radon, which as a gas can enter the body far more readily than can its parent radium.
== Overdose == Zopiclone is sometimes used as a method of suicide. It has a similar fatality index to that of benzodiazepine drugs, apart from temazepam, which is particularly toxic in overdose. Deaths have occurred from zopiclone overdose, alone or in combination with other drugs. Overdose of zopiclone may present with excessive sedation and depressed respiratory function that may progress to coma and possibly death. Zopiclone combined with alcohol, opiates, or other central nervous system depressants may be even more likely to lead to fatal overdoses. Zopiclone overdosage can be treated with the GABAA receptor benzodiazepine site antagonist flumazenil, which displaces zopiclone from its binding site, thereby rapidly reversing its effects. Serious effects on the heart may also occur from a zopiclone overdose when combined with piperazine. Zopiclone is one of the most common drugs in drug poisoning suicides in elderly. When taken alone, it usually is not fatal, but when mixed with alcohol or other drugs such as opioids, or in patients with respiratory, or hepatic disorders, the risk of a serious and fatal overdose increases.
=== Pharmacokinetic === Nicotine and cigarette smoke both induce the expression of liver enzymes (e.g., certain cytochrome P450 proteins) which metabolize drugs, leading to the potential for alterations in drug metabolism.
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.